Navigation Links
New Study Shows Zylast Antiseptic Products Kill More than 99.99% of E. Coli, Other Bacteria, on Contact
Date:12/7/2012

TARRYTOWN, N.Y., Dec. 7, 2012 /PRNewswire/ -- Innovative BioDefense Inc, the creators of the Zylast® line of antimicrobial products, announced today that a new round of extensive time-kill testing on the Zylast products showed that more than 99.99 percent of disease-causing germs were destroyed within 15 seconds, making Zylast the most effective antimicrobial on the market.  The Zylast products, including an alcohol-based antiseptic, a water-based antiseptic lotion, and a foaming hand soap, were tested against a range of 25 different bacteria. 

The list of bacteria tested is standard, and was developed to ensure a broad, representative spectrum of organisms was evaluated.  Among the bacteria tested were E. Coli, a leading cause of food poisoning, S. Pneumoniae, a primary source of pneumonia and meningitis, and Acinetobacter baumannii, a drug-resistant bacteria that causes many fatal hospital infections and is prevalent in soldiers wounded in Iraq and Afghanistan.

Two of the most prevalent and dangerous of these drug-resistant bacteria are Methicillin-Resistant S. aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE).  Testing was performed with the Zylast Antiseptic against both of these deadly bacteria.  Not only did the Antiseptic destroy more than 99.99% of these bacteria on contact, it was still killing more than 90% of both VRE and MRSA one hour after it was applied.

All Zylast products have been shown to be persistent for six hours, and now have demonstrated rapid, broad-spectrum kill as well.  In-vitro testing on skin substitutes has shown that all Zylast products are still killing at or above 97% of disease-causing bacteria at 1 hour, and remaining above 90% at 4 hours after application.

When the Zylast Antiseptic was tested, it was shown to be more than 100 times more effective against Norovirus than alcohol alone (Liu et al, BioScience Results).  Previous t
'/>"/>

SOURCE Innovative BioDefense Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ) ... and long-term growth strategies at a meeting with the ... . President and Chief Executive Officer Mike ... has to bring forward meaningful innovation to transform patient ... shareholder value. "We are focused on ...
(Date:5/1/2015)... May 1, 2015 Cambrex Corporation (NYSE: CBM ... 2015. Highlights , Sales increased ... 27% excluding foreign currency impact, driven by Innovator products and ... $8.4 million in the first quarter of 2014. , ... in the first quarter last year and Adjusted Diluted EPS ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
... magazine has ranked Universal SmartComp #503 overall and #35 ... 5000, an exclusive ranking of the nation,s fastest-growing private ... the most important segment of the economy—America,s independent-minded entrepreneurs. ... and Radio Flyer, maker of the iconic children,s red ...
Cached Medicine Technology:Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3
(Date:5/3/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... She has worked to enhance the well being of the men, ... generalist in a hospital, followed by providing care for families in ... with as an Adult Nurse Practitioner began wondering if I could ... the birth of my own children with my mentor Nurse Midwife, ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... 2015 " Bubbly Walrus ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... game. , The best games to play on smartphones are ... users killing brain cells with a video game that just ...
(Date:5/3/2015)... 2015 “ BolehVPN ” was featured on ... the latest and coolest technology products available to consumers. Scott ... the review and shared with viewers how to protect their ... days is on computers and even more so online. It ... people all over the world. In terms of work, the ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 NuevaCare announced ... at two upcoming area seminars. The first event will ... Annual Regional Stroke Conference to be held at The ... on Wednesday, May 13 during the Dementia Conference to ... , “These seminars offer an excellent opportunity to learn ...
Breaking Medicine News(10 mins):Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... found out that a protein called NMNAT can delay the ... level. The researchers from Baylor College of// Medicine in a ... online today said that NMNAT protects against nerve cell degeneration ... the question if a drug might be developed that could ...
... wines that belong to the vineyards of France and Italy are ... effects of fatty meals on the heart can be offset by ... has shown. Wines from these regions contain high levels of a ... have also proved the heart healthy benefits of a daily glass ...
... Center and colleagues at four other medical centers have ... that may contribute to early atherosclerosis. ,“If we ... life who have a genetic predisposition to develop atherosclerosis, ... and stroke sooner and more aggressively,” said David Herrington, ...
... a new drug that might cease men from ejaculation during ... on is that the contraction of the longitudinal muscle in ... out of the penis. ,This method of contraception ... to which researchers claim have chemicals to block male sperms. ...
... unknown immunodeficiency disease was discovered by scientists about twenty-five ... 'AIDS'. //Ever since, 'Acquired Immune Deficiency Syndrome' or AIDS, ... to the latest figures enabled by the UNAIDS/WHO 2006 ... world are grappling with the disease. ,AIDS ...
... Research, the data from Population Based Cancer Registry, Delhi ... specific// incidence rates of breast cancer below 40 years ... National Cancer Control Programme (NCCP), special emphasis is now ... awareness. Grant-in-aid is provided to Non-Governmental Organisations to create ...
Cached Medicine News:Health News:NMNAT Protein Protects Against Nerve Cell Degeneration 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 2Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 3Health News:'Red'y to Fight HIV – 'AbstinenceBehaviorCondom', Sacrosanct to AIDS Preventio 4
... proteins produced with recombinant technology, that have been ... capable of detecting the different types of T.cruzi ... with amino acid sequences repeated in tandem. SAPA ... phase of the infection, it reacts with 93% ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
... defibrillator lead features a patented ... flexibility and maneuverability of a ... physician who prefers a lead ... SPL lead also promotes low ...
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
Medicine Products: